Embryo transfer is now a widespread assisted reproductive technique for bovine industry. In general, there are two methods for the production of bovine blastocysts, namely development of blastocysts *in vitro* and *in vivo*. Although embryos of both origins have similar contributions regarding cattle production, there is a fundamental biological difference in the quality of the embryos. In general, the pregnancy rate of the *in vivo* produced blastocysts has been higher than that of *in vitro* developed blastocysts. In addition, a higher rate of embryonic degeneration has been reported for *in vitro* produced blastocysts \[[@r1]\]. Early studies comparing embryos produced *in vitro* and *in vivo* have reported differences in cleavage speed and weights of resultant calves \[[@r2], [@r3]\], which were attributed to the *in vitro* culture conditions \[[@r4], [@r5]\]. Recent studies, using current genomic analysis technologies, have revealed differences in gene expression, as well as different methylation patterns, between *in vitro* and *in vivo* developed embryos, thereby highlighting that these differences originate from changes in the molecular background \[[@r6], [@r7]\]. This information is useful in identifying abnormalities in blastocysts developed *in vitro* and in improving culture conditions for *in vitro* embryo productions. Due to difficulties in obtaining large numbers of embryo produced *in vivo*, studies about the differences between *in vitro* and *in vivo* produced embryos are few. In the present study, we examined gene expression in embryos using next-generation sequencing technology and addressed the differences in mitochondrial number and function between embryos with two different origins.

Materials and Methods {#s1}
=====================

Chemicals
---------

All the drugs used in this study were purchased from Nacalai Tesque (Kyoto, Japan) unless stated otherwise. Medium 199 supplemented with 10% fetal cow serum (FCS) (FCS; 5703H; ICN Pharmaceuticals, Costa Mesa, CA, USA) and 5 mM taurine was used for maturation (IVM medium). Synthetic oviductal fluid (SOF) was used for *in vitro* fertilization (IVF) and *in vitro* culture (IVC) \[[@r8]\]. For IVF, SOF was supplemented with 5 mg/ml BSA (Bovine Serum Albumin-fatty acid free) and 10 U/ml heparin (Sigma-Aldrich, St Louis, MO, USA). For IVC, SOF was supplemented with essential and non-essential amino acids (Sigma-Aldrich), 1% FCS, 5 mM taurine, and 1.5 mM glucose.

Ovary and oocyte collection
---------------------------

Ovaries were collected from Japanese Black cows at a slaughter house and stored at 25°C in phosphate-buffered saline (PBS) containing 10 mM glucose, 10 mM sucrose, and antibiotics, and were transported to the laboratory within 4 h. Cumulus oocyte complexes (COCs) were collected from ovaries of each cow using a syringe with an 18-G needle.

In vitro maturation and fertilization
-------------------------------------

COCs were matured in IVM medium for 21 h (10 COCs/100 μl drop). After maturation, the complexes were washed with IVF medium and co-incubated with frozen-thawed semen from a Japanese black bull. For fertilization, the semen was washed with a 45--60% Percoll solution (Amersham Biosciences, Uppsala, Sweden) to create a discontinuous gradient for centrifugation (800 × *g* for 10 min). The sperm and COCs were co-incubated for 6 h (The sperm concentration in the IVF medium 1 × 10^6^ cells/ml), and the COCs were transferred in IVC medium containing 1% FCS.

In vitro culture of embryos
---------------------------

After fertilization, COCs were cultured for 2 days in IVC medium. Subsequently, the cleaved embryos over 7 cell-stages were removed from the surrounding cumulus cells and transferred to a new 50 μl droplet of IVC medium and further cultured for 5 days. The atmospheric culture conditions were 5% CO~2~ in air for IVM, IVF, and first IVC (until 48 h post insemination), and 5% CO~2~, 5% O~2~, and 90% N~2~ for second IVC (from 48 h to 7 days post insemination). After 7 days of IVC, the quality of the obtained blastocysts was evaluated using the International Embryo Technology Society (IETS) manual \[<https://www.iets.org/pub_manual.asp>\], and only embryos categorized as grade 1 or 2 were used for further experiments.

Superovulation and flushing of embryos
--------------------------------------

Fifteen Japanese Black cows were used for *in vivo* embryo production. Cows with corpus luteum were inserted with a progesterone-releasing intravaginal device (controlled internal drug release (CIDR), Livestock improvement corporation, Tokyo Japan). The day of CIDR insertion was defined as day 0. On day 1 Estradiol benzoate (Asuka, Tokyo, Japan) was administered (2 mg) and on day 6 cows were administered FSH (total 20 AU, Antrin, Kyoritsu, Tokyo, Japan) for three days. On the morning of day 8, the cows were treated with PGF2α (d-cloprostenol, Dalmazin, Kyoritsu, Tokyo, Japan) and the CIDR was removed. Two days after the PGF2α treatment, artificial insemination was performed. Frozen-thawed semen from the same Japanese black bull was used for *in vitro* fertilization. Resulting embryos were non-surgically flushed from the uterus at 6.5 days after insemination. The embryos were classified using the IETS manual and only embryos categorized as grade 1 were used for further experiments. Superovulation from cows was approved by the Ethical Committee for Animal Experiment of Tokyo University of Agriculture.

Assessment of mitochondrial DNA copy number
-------------------------------------------

Mitochondrial DNA copy number (Mt number) in blastocysts was determined by real time PCR. Each blastocyst was lysed in 6 μl of lysis buffer (20 mM Tris, 0.4 mg/ml proteinase K, 0.9% Nonidet-P40, and 0.9% Tween 20) at 55°C for 30 min and then at 95°C for 5 min. Mt number was determined by real-time PCR using the Rotor-Gene 6500 real-time rotary analyzer (Corbett Research, Sydney, Australia). The PCR primer set was designed using the Primer3Plus tool based on the bovine mitochondrial complete genome sequence (NC_006853.1) (5′- ACCCCTTGTACCTTTTGCAT -3′ and 5′- TCTGGTTTCGGGCTGCTTAG -3′, 81 bp). The PCR conditions were as follows: an initial denaturation at 95°C for 1 min, followed by 40 cycles at 98°C for 5 sec and at 60°C for 10 sec. A standard curve was generated for each run using 10-fold serial dilutions representing the copy number of the external standard. The external standard was the PCR product of the corresponding gene cloned into a vector using the Zero Blunt TOPO PCR cloning kit (Invitrogen, Carlsbad, CA, USA), which was sequenced before use. The amplification efficiency in all trials was \> 1.98.

ATP assay
---------

The ATP content of embryos was measured as luminescence generated in an ATP-dependent luciferin--luciferase bioluminescence assay (ATP assay kit; Toyo-Inc., Tokyo, Japan). Individual embryos were lysed and luminescence was measured immediately using a plate-reader (Sperk 10M Tekan, Tokyo, Japan).

Immunostaining
--------------

Embryos were fixed in 4% paraformaldehyde and were incubated in PBS containing 0.9% TritonX-100 for 30 min followed by incubation in PBS containing 5 mg/ml BSA. The primary antibody used was rabbit anti-TOMM20 (Santacruz Biotech, Dallas, TX, USA, 1:200) and the secondary antibody was anti-rabbit IgG Fab2 conjugated with Alexa Fluor 555 (Cell signaling). The embryos were then mounted on glass slides using an antifade reagent (Invitrogen) and were observed under a fluorescent microscope (DMI 6000 B; Leica, Wetzlar, Germany).

Transcriptome analysis
----------------------

Twenty-four *in vivo* produced blastocysts were collected from 6 Japanese Black cows following superovulation (4 blastocysts from each cow, Grade 1 and 2 according to the IETS standard) and were used for RNA-seq. Moreover, 200 blastocysts produced *in vitro* using 100 Japanese Black cows were used for RNA-seq.

Total RNA was extracted from blastocysts using the RNAqueous kit (Life Technologies, Carlsbad, CA, USA). The RNA quality was confirmed using the 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and cDNA libraries were prepared using the TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA, USA). Library quality and quantity were determined using the Agilent 2100 Bioanalyzer and the KAPA Library Quantification Kit (KAPA Biosystems, Wilmington, MA, USA), respectively. Clusters were generated on a cBot (Illumina) and one lane of the multiplied samples was sequenced as 100 bp reads (single read) on the HiSeq 2500 (Illumina). Image analysis, base calling, and quality filtering were performed using the bcl2fastq2 (Illumina) software according to the manufacturer's instructions. Sequence data were filtered to discard adapter sequences, ambiguous nucleotides, and low-quality sequences. The remaining sequence data were aligned to the Bos Taurus genome sequence (ARS-UCD1.2/bosTau9) to count sequence reads. Using mapped sequence data, expression values for each gene and statistical analysis of differentially expressed genes were determined. Filtering, mapping, and subsequent analysis were performed using the CLC Genomics Workbench software (Qiagen, Redwood City, CA, USA). Statistical significance was determined byempirical analysis using DGE tool \[[@r9]\]. Differentially expressed genes (fold-change ≥ 2.0, FDR adjusted P \< 0.05, and q \< 0.2 \[[@r10]\]) were used for further analyses. To predict upstream transcriptional regulators, genes that had significant differences in expression were interpreted using the upstream regulator function of the Ingenuity Pathway Analysis software (IPA, Qiagen). This helped to determine how many known targets of each transcriptional regulator were present in the differentially expressed gene list and calculated overlapping P values to measure statistically significant overlap. Fisher's exact test was used in the analysis of gene set enrichment in each functional category and significance was generally attributed to a P value of less than 0.01. Gene expression analysis data have been registered (DRA006210).

Statistical analysis
--------------------

Mitochondrial number, total cell number, fluorescent intensity following immunostaining, and ATP contents between the two types of blastocysts were compared using the Student's *t*-test. P-values \< 0.05 were considered statistically significant.

Results {#s2}
=======

Differentially expressed genes between embryos produced in vitro and in vivo
----------------------------------------------------------------------------

In First, we selected significantly overexpressed genes (2.5-fold difference) in embryos produced either *in vitro* (No.2488) or *in vitro* (No. 1174) and analyzed them using a functional annotation tool (DAVID software, <https://david.ncifcrf.gov/>). As shown in [Table 1](#tbl_001){ref-type="table"}Table 1.Functional annotation (Kegg pathway) of genes expressing greater (2.5-fold) in embryos *in vitro* or *in vivo*OriginTermP-ValueVITROFocal adhesion7.24151E-11ECM-receptor interaction1.8947E-09PI3K-Akt signaling pathway1.3372E-06Oxytocin signaling pathway3.22306E-06Protein digestion and absorption1.1462E-05VIVOOxidation-reduction process3.37163E-16Mitochondrion organization3.79235E-12Mitochondrial translation7.73522E-12Cellular respiration4.16333E-11Respiratory electron transport chain5.72642E-10, genes expressed higher in *in vitro* produced blastocyst were annotated in Focal adhesion, extracellular matrix (ECM)-receptor interaction and PI3K-Akt signaling and the genes which expressed higher in *in vivo* produced embryos were annotated to Oxidation-reduction process, mitochondrion organization, and mitochondrial translation. As such, we compared the expression of genes associated with mitochondrial proteins. Interestingly, genes coded in the mitochondrial genome had lower expression levels, whereas the nuclear-encoded genes associated with mitochondrial proteins had higher expression levels in embryos produced *in vivo* compared with those produced *in vitro* ([Table 2](#tbl_002){ref-type="table"}Table 2.The number of differentially expressed nuclear and mitochondrial genes encoding mitochondrial proteinsNo of genesOriginLocationTotalDownUpMitochondria19190NucleusInner membrane58553Outer membrane23518Matrix821963Cytoplasmic side24718Integral membrane591346Down; Fold change \< --1.0, Up; Fold change \> 1.0.). Furthermore, IPA revealed 194 upstream regulators ([Supplementary Table 1](#pdf_001){ref-type="supplementary-material"}: online only), which included miRNAs, as activators in embryos produced *in vivo* and trichostatin A, 5-azacitidine, hydrogen peroxide, p38MAPK, ERK, and caspase as activators in blastocysts produced *in vitro* ([Table 3](#tbl_003){ref-type="table"}Table 3.A part of the upstream regulators of differentially expressed genes between embryos developed *in vivo* and *in vitro*Chemical drugActivation in VIVOP valueActivation z-scorecurcumin2.7410.00584mir-2103.0960.000303mir-172.5370.000852mir-102.3410.00171mir-152.2140.0293mir-1932.530.0377mir-253.1060.04815-azacytidine--2.7750.00384Akt--3.7850.00412caspase--2.0350.00296Creb--2.5410.0000136D-glucose--2.1845.39E-11ERK--3.030.0000464hydrogen peroxide--3.5890.000283NFkB (complex)--2.3210.000851P38 MAPK--3.8520.00606Tgf beta--3.9420.00164trichostatin A--2.4030.00000227Vegf--2.0778.86E-08).

We further assessed mitochondrial number and function in the blastocysts. Mitochondrial DNA copy number in *in vivo* produced blastocysts was 130,793 ± 21,527 which was significantly less than that of *in vitro* produced embryos (P \< 0.01, 180,560 ± 30,426, [Fig. 1-A](#fig_001){ref-type="fig"}Fig. 1.Mitochondrial DNA copy number (A) and ATP contents in blastocyst produced *in vitro* and *in vivo*. ^a--b^ P \< 0.05.). ATP content in *in vivo* produced embryos was less than that observed in *in vitro* produced embryos (0.40 ± 0.1 and 2.3 ± 0.2, P \< 0.01, [Fig. 1-B](#fig_001){ref-type="fig"}). The high mitochondrial copy number in embryos produced *in vitro* was confirmed by the high expression levels of TOMM20 in these embryos (1.44-fold, P \< 0.01, [Fig. 2-A](#fig_002){ref-type="fig"}Fig. 2.TOMM20 expression levels (A) and total cell number of blastocysts (B) produced *in vitro* and *in vivo*. Fluorescent intensity of the embryos developed *in vivo* was defined as 1.0. (C) Representative image of embryos. ^a--b^ P \< 0.05.). When observing the embryos in a bright field, the *in vivo* produced embryos looked more transparent, but the total cell number was similar between the two blastocysts groups ([Fig. 2-B](#fig_002){ref-type="fig"}).

Discussion {#s3}
==========

This study investigated the gene expressions in blastocysts produced *in vitro* and *in vivo* and demonstrated differential backgrounds with upstream regulators and pathways of the differentially expressed genes. In addition, we found significant differences in mitochondrial number and ATP contents between blastocysts produced *in vitro* and *in vivo*.

Until now, studies reporting on the differences in gene expression between embryos produced *in vitro* and *in vivo* relied on using reverse transcription PCR with housekeeping genes H2A, B2M, ACTB, GAPDH, and others as controls \[[@r11]\]. However, our results revealed differences in the expression levels of the housekeeping genes between *in vitro and in vivo* produced embryos ([Supplementary Table 2](#pdf_001){ref-type="supplementary-material"}: online only). Therefore, the results of previous gene expression studies should be carefully evaluated. After functionally annotating genes with significant difference between groups, we found that gene upregulation in *in vitro* embryos was associated with Focal adhesion, ECM-receptor interaction and PI3K-Akt signaling. The results indicated that *in vitro* culture conditions upregulate interactions between embryos and the culture environment. We further explored the upstream regulators of the differentially expressed genes by IPA analysis. Predicted activation factors of embryos produced *in vitro* (N.134) included trichostatin A and 5-azacitizine, which indicated hyperacetylation and hypomethylation in embryos produced *in vitro*. Consistent with our results, previous studies have reported that *in vitro* culture conditions induce changes in methylation and acetylation \[[@r12]\]. Additionally, hydrogen peroxide, p38 MAPK, caspase, and NFκB have also been predicted as upstream regulators. The results indicate that certain adverse factors in the culture conditions and cellular stress including reactive oxygen species and apoptosis, may present *in vitro* produced embryos. Interestingly, several microRNAs were presumed to act as activation upstream regulators for embryos developed *in vivo*. There have been very few reports about the function of these miRNAs in bovine embryo development. They are present in the exosomes in bovine oviductal fluids and uterine fluids, and the hypothesis that miRNAs are upstream regulators suggests that certain miRNAs regulate embryo development *in vivo*. Functional annotation of genes upregulated in *in vivo* embryos showed that genes associated with mitochondria are a promising avenue for differential gene expression between blastocysts produced *in vitro* and *in vivo*. Nuclear coded mitochondrial genes had higher expression levels whereas mitochondrial genome coded genes had lower expression levels in embryos produced *in vivo* ([Table 3](#tbl_003){ref-type="table"}). These results indicate that the mitochondria in embryos are differentially regulated between *in vitro* and *in vivo* conditions. In the case of oocytes, greater mitochondrial content is an indicator of good oocytes \[[@r13], [@r14]\] whereas this is not the case in blastocysts. Recently, several studies reported that low mitochondrial content was linked to a high developmental ability of the blastocysts \[[@r15], [@r16]\]. In addition, high mitochondrial DNA copy number was found in equine blastocysts produced *in vitro* as compared with embryos produced *in vivo* \[[@r17]\]. Furthermore, high mitochondrial DNA content is reported to be associated with aneuploidy of the embryos \[[@r18], [@r19]\]. The results of the current study showed that although the total cell number was the same, mitochondrial DNA copy number and expression levels of TOMM20 (outer mitochondrial membrane protein) were higher for blastocysts produced *in vitro*. ATP generation is one of the main mitochondrial functions and ATP is one of the markers that reflect the quality of oocytes \[[@r20], [@r21]\]. Though ATP content in bovine blastocysts produced *in vitro* and *in vivo* has not been extensively investigated, an earlier study \[[@r22]\] reported that culturing embryos *in vitro* increased the ATP content in mouse blastocysts. In the present study, we observed significantly high ATP content in blastocysts produced *in vitro*. These findings suggest that mitochondrial activity is abnormally high in *in vitro* culture conditions. The limitation of the present study is that we used *in vitro* matured, fertilized, and cultured blastocysts, as well as superovulated blastocysts. Each *in vitro* step, as well as the superovulation process, may have affected embryo quality \[[@r23]\]. In the present study, we used blastocysts developed *in vivo* (6.5 days post insemination), which are younger than those from embryos produced *in vitro* (7.0 days after fertilization). In addition, the timing of fertilization, *i.e.,* the timing of ovulation and sperm-oocyte interaction in the oviduct is unclear for embryos produced *in vivo*. This difference is likely linked to differential gene expression in the different developmental stages of embryos. Therefore, we cannot define a causal factor for the differences found between *in vivo* and *in vitro* produced embryos. Furthermore, studies using a greater number of cows are required.

In conclusion, the gene expression levels differ between embryos produced *in vitro* and *in vivo* and mitochondrial quantity and function extensively differ between the two kinds of blastocysts.

Supplementary
=============

###### Supplement Tables
